GNRH1 and pachyonychia congenita: Recently some real-world data from a national database comparing CV outcomes in PC cases treated with degarelix versus LHRH agonists have been published, while no relevant studies are reported in literature comparing abarelix and LHRH agonists in terms of CV morbidity.